May 4, 2017 10:15 AM EDTUpdated 11:42 AM
News Briefing

For­mer GSK can­cer R&D chief Pao­let­ti takes the reins at Gam­maDelta; Blue­print inks big Cam­bridge lease

Shehla Shakoor

Managing Director

→ Pao­lo Pao­let­ti, the for­mer pres­i­dent of GSK’s on­col­o­gy R&D group, has tak­en the helm at Abing­worth-backed Gam­maDelta Ther­a­peu­tics. “I’m ex­treme­ly ex­cit­ed to take …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times